Sylvester Comprehensive Cancer Center

  • 20160793 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20160793

    SDG: Pediatric Cancer
    Disease Site(s):

    Soft Tissue

    Sponsor: Moffitt Cancer Center

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults

    Eligibility Criteria - NCT02945800 *This information has been extracted from " www.clinicaltrials.gov"

  • ANBL1232 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20161103

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma

    Eligibility Criteria - NCT02176967 *This information has been extracted from " www.clinicaltrials.gov"

  • ARST1431 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20170069

    SDG: Pediatric Cancer
    Disease Site(s):

    Soft Tissue

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

    Eligibility Criteria - NCT02567435 *This information has been extracted from " www.clinicaltrials.gov"

  • AGCT1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20170605

    SDG: Pediatric Cancer
    Disease Site(s):

    Other Female Genital,Other Male Genital,Ovary

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

    Eligibility Criteria - NCT03067181 *This information has been extracted from " www.clinicaltrials.gov"

  • AALL1631 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20170840

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    AALL1631:International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.

    Eligibility Criteria - NCT03007147 *This information has been extracted from " www.clinicaltrials.gov"

  • ADVL1521 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20180133

    SDG: Pediatric Cancer
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    ADVL1521: A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

    Eligibility Criteria - NCT03190915 *This information has been extracted from " www.clinicaltrials.gov"

  • ANBL1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20180624

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    ANBL1531 : A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)) (IND# 134379)

    Eligibility Criteria - NCT03126916 *This information has been extracted from " www.clinicaltrials.gov"

  • AHEP1531 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20180800

    SDG: Pediatric Cancer
    Disease Site(s):

    Liver

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

    Eligibility Criteria - NCT03533582 *This information has been extracted from " www.clinicaltrials.gov"

  • 19487 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20181082

    SDG: Pediatric Cancer
    Disease Site(s):

    Bones and Joints

    Sponsor: Moffitt Cancer Center

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    19487: A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma

    Eligibility Criteria - NCT03628209 *This information has been extracted from " www.clinicaltrials.gov"

  • T2017-002 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20190180

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: THERAPEUTIC ADVANCES IN CHILDHOOD LEUKEMIA

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    T2017-002 : A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730

    Eligibility Criteria - NCT03817320 *This information has been extracted from " www.clinicaltrials.gov"

  • ACNS1422 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20190523

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

    Eligibility Criteria - NCT02724579 *This information has been extracted from " www.clinicaltrials.gov"

  • AGCT1532 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20190525

    SDG: Pediatric Cancer
    Disease Site(s):

    Other Urinary,Prostate

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Phase 3 Accelerated BEP: A Randomised Phase 3 Trial Of Accelerated Versus Standard BEP Chemotherapy For Patients With Intermediate And Poor-Risk Metastatic Germ Cell Tumours

    Eligibility Criteria - NCT02582697 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191014 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20191014

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia,Non-Hodgkin Lymphoma

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

    Eligibility Criteria - NCT03914625 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191015 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20191015

    SDG: Pediatric Cancer
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

    Eligibility Criteria - NCT03817398 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191078 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20191078

    SDG: Pediatric Cancer
    Disease Site(s):

    Brain and Nervous System

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

    Eligibility Criteria - NCT03919071 *This information has been extracted from " www.clinicaltrials.gov"

  • LOXO-101 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20191079

    SDG: Pediatric Cancer
    Disease Site(s):

    Leukemia, Other

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

    Eligibility Criteria - NCT03834961 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191175 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20191175

    SDG: Pediatric Cancer
    Disease Site(s):

    Leukemia, Other,Lymphoid Leukemia

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

    Eligibility Criteria - NCT03959085 *This information has been extracted from " www.clinicaltrials.gov"

  • APEC1621A - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20191246

    SDG: Pediatric Cancer
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

    Eligibility Criteria - NCT03213704 *This information has been extracted from " www.clinicaltrials.gov"

  • APEC1621F - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20191254

    SDG: Pediatric Cancer
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

    Eligibility Criteria - NCT03213652 *This information has been extracted from " www.clinicaltrials.gov"

  • APEC1621l - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20191257

    SDG: Pediatric Cancer
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

    Eligibility Criteria - NCT03526250 *This information has been extracted from " www.clinicaltrials.gov"

  • APEC1621SC - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:
    RCemailImg Nuria Garantiva
    RCphone +1 (786) 2743477

    IRB: 20191259

    SDG: Pediatric Cancer
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

    Eligibility Criteria - NCT03155620 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201135 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20201135

    SDG: Pediatric Cancer
    Disease Site(s):

    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

    Eligibility Criteria - NCT04293562 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210237 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    Coordinator:

    IRB: 20210237

    SDG: Pediatric Cancer
    Disease Site(s):

    Kidney

    Sponsor: COG

    Enrolling Sites:

    Sylvester

    Title:

    A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

    Eligibility Criteria - NCT03595124 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210234 - Dhir Aditi

  • Investigator:
    Aditi Dhir
    RCname Email

    Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20210234

    SDG: Pediatric Cancer
    Disease Site(s):

    Soft Tissue

    Sponsor: Moffitt Cancer Center

    Enrolling Sites:

    Sylvester

    Title:

    Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

    Eligibility Criteria - NCT04388839 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160415 - St. George Sara

  • Investigator:
    Sara St. George
    RCname Email

    Coordinator:

    IRB: 20160415

    SDG: Population Sciences
    Disease Site(s):

    Multiple

    Sponsor: NHLBI

    Enrolling Sites:

    Community Clinics
    JMH
    Sylvester
    UMH

    Title:

    St. George K01: Family-based eHealth Obesity Prevention Intervention for Hispanic Adolescents

    Eligibility Criteria - NCT03986190 *This information has been extracted from " www.clinicaltrials.gov"

  • KTE-C19-104 - Ziga, Edward

  • Investigator:
    Edward Ziga
    RCname Email

    Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20160129

    SDG: Pediatric Cancer
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: Kite

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)

    Eligibility Criteria - NCT02625480 *This information has been extracted from " www.clinicaltrials.gov"